New products

Up climbing

Enjoy upgraded performance with the Up Rise VCS, a medium-stiff, high-performance climbing shoe featuring a full outsole, improved heel cup and extended toe rand. Extra arch supports support sling shots!

Learn more

New products

Updated Byte

Think big by thinking small. Don't be fooled by its size. Byte is equipped with a battery lockout, asymmetrical single arm bracket, easily accessible battery door enclosure, and large push button switch, all at a mere 64 grams.

learn more

Sierra designs

sweet suite 2

Tent architecture so unique it creates the perfect combination of lightweight, liveable space.

Learn more
Edelweiss

Edelweiss

Edelweiss has always supported alpine and sport climbing pioneers by developing climbing ropes adapted to their ambitions.

For high level exploits, recreation or safety at work, Edelweiss continues to offer a wide product for athletes and operators of modern vertical activities. With this long experience, punctuated by constant innovation and quality research, Edelweiss is a key player in the vertical world.

The history of Edelweiss is landmarked by major innovations which supported the evolution of mountaineering and climbing.
  • 1953 : First sheath/core construction rope.
  • 1971 : Development of Everdry, dry treatment of the sheath, with Reinhold Messner.
  • 1984 : First rope to sustain Sharp Edge test (factor 2 fall on a 0.75mm radius edge).
  • 1991 : Perdur treatment to improve abrasion resistance.
  • 1993 : Supereverdry, dry treatment of both sheath and core for even more performance in extreme conditions.
  • 2003 : Introducing the buckle-free harness.
  • 2009 : O-Flex Concept, for a better handling and more durability on ropes used on an intensive basis.
  • 2010 : Perform 3, a new generation of ropes, smoother, more fluid, lightweight and still as enduring.
  • 2011 : Alpha and Omega harness concepts, for more support and comfort.
  • 2014 : Awarding of the UIAA Water repellent label on 8 model of dynamic ropes, the water absorption is in average limited at 1,1%.